Status:

COMPLETED

An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females

Lead Sponsor:

AbbVie (prior sponsor, Abbott)

Collaborating Sponsors:

Neurocrine Biosciences

Conditions:

Folliculogenesis

Eligibility:

FEMALE

18-40 years

Phase:

PHASE1

Brief Summary

This is an open-label Phase 1 study in healthy premenopausal females evaluating the effects of different dosing regimens of elagolix on ovarian activity, ovulation, and ovarian reserve and to assess t...

Detailed Description

This is an open-label, multiple-dose, Phase 1 study in premenopausal subjects aged 18 years to 40 years, with a history of regular menstrual cycles (24 to 32 days long) and no evidence of significant ...

Eligibility Criteria

Inclusion

  • \- Premenopausal female, between 18 and 40 years of age, inclusive - History of regular menstrual cycles - Endocrine and ultrasonographic evidence of ovulation and normal ovulatory cycle during the screening period - Follicle-stimulating hormone level of \<35 mIU/mL - Agrees to use required birth control methods during the entire length of participation in the study

Exclusion

  • \- Screening ultrasound results show a clinically significant gynecological disorder - Surgical history of hysterectomy without oophorectomy, unilateral or bilateral oophorectomy, removal of ovarian cysts - Less than 6 months postpartum or post-lactation at the start of study drug dosing - Pregnant or breast feeding or is planning a pregnancy within the next 12 months - Testosterone concentration \>120 ng/dL at screening

Key Trial Info

Start Date :

June 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2012

Estimated Enrollment :

216 Patients enrolled

Trial Details

Trial ID

NCT01403038

Start Date

June 1 2011

End Date

November 1 2012

Last Update

January 8 2013

Active Locations (22)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (22 locations)

1

Site Reference ID/Investigator# 50805

Colorado Springs, Colorado, United States, 80910

2

Site Reference ID/Investigator# 51270

Colorado Springs, Colorado, United States, 80917

3

Site Reference ID/Investigator# 50884

Denver, Colorado, United States, 80246

4

Site Reference ID/Investigator# 50404

Lonetree, Colorado, United States, 80124

An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females | DecenTrialz